ACTRN12621000170820进行中（未招募）2 期
Safety of Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis in Adults with no Treatment Alternatives
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Prior participant in an Avalyn AP01 study, excluding normal volunteers
- •2.Patients with no other treatment options with Interstitial Lung Diseases, including but not limited to Idiopathic Pulmonary Fibrosis, fibrosing phenotype Interstitial Lung Disease, pulmonary involvement of scleroderma, rheumatoid lung and silicosis. Prior Sponsor approval of non-Avalyn study rollover patients is required.
- •3.Diagnosed chronic progressive fibrotic Interstitial Lung Disease, including Idiopathic Pulmonary Fibrosis, without treatment alternatives such as:
- •a.Not eligible for oral pirfenidone and nintedanib due to national formulary restrictions or lack of regulatory approval
- •b.Intolerant to oral pirfenidone and nintedanib, if previously offered
- •c.Not eligible for an ongoing clinical study of AP01 other than this study
- •4.Age greater than 18 years
- •5.Able to understand and sign a written informed consent form (ICF)
- •6.Able to understand the importance of adherence to study treatment and the study protocol and willing to follow all study requirements, including the concomitant medication restrictions, throughout the study
- •7.Females of childbearing potential (FOCBP) must use a contraceptive method during the clinical study and 30 days after the last dose of pirfenidone solution for inhalation (AP01)
排除标准
- •Disease-Related Exclusions
- •1.Significant clinical worsening of Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis for AP01 naïve patients between Screening and Day 1, in the opinion of the investigator
- •2.Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, in the opinion of the investigator
- •3.History of acute Idiopathic Pulmonary Fibrosis exacerbation requiring hospitalization in the last 30 days
- •4.Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
- •Medical Exclusions
- •5.Females with a positive pregnancy test at Screening (AP01 naïve patients) or Baseline (Rollover patients from previous study) or are currently breastfeeding
- •6.Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 6 months. This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma)
- •7.Any condition other than Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis that, in the opinion of the investigator, is likely to result in the death of the patient within the next 6 months
- •8.History of severe hepatic impairment or end-stage liver disease or AST or ALT greater than 5 times the upper limit of normal at Screening (AP01 naïve patients)
- •9.History of end-stage renal disease requiring dialysis
- •10.Participation in a clinical study with administration of an investigational drug product within the previous 30 days, or five half-lives of the previously administered investigational product (IP) (AP01 naïve patients only)
研究者
相似试验
招募中
2 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisInterstitial Lung Disease (ILD) which cause inflammation and scarring (firbrosis) of the lungs10038716NL-OMON52355Avalyn Pharma, Inc4
进行中（未招募）
1 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisInterstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)MedDRA version: 21.1Level: PTClassification code 10022611Term: Interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005103-39-CZAvalyn Pharma, Inc.100
招募中
2 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis2024-515964-30-00Avalyn Pharma Inc.33
进行中（未招募）
1 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisEUCTR2020-005103-39-PLAvalyn Pharma, Inc.100
进行中（未招募）
1 期
Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosisMedDRA version: 20.0Level: LLTClassification code 10022612Term: Interstitial lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10035754Term: Pneumonitis hypersensitivitySystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10025088Term: Lung fibrosisSystem Organ Class: 100000004855MedDRA version: 20.0Level: LLTClassification code 10022617Term: Interstitial pneumoniaSystem Organ Class: 100000004855EUCTR2014-000861-32-DEJustus Liebig Universität Giessen374